JAZZ PHARMACEUTICALS PLC (JAZZ)

Jazz Pharmaceuticals to Report 2024 First Quarter Financial Results on May 1, 2024

/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2024 first quarter financial results on Wednesday, May 1, 2024,...

Jazz Pharmaceuticals is Now Oversold (JAZZ)

Jazz Pharmaceuticals to Showcase Expansive Neuroscience Portfolio at American Academy of Neurology Annual Meeting

/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that 13 abstracts from across its neuroscience portfolio and pipeline, including two...

Jazz Pharmaceuticals Completes Zanidatamab Biologics License Application for Previously Treated HER2-Positive Metastatic Biliary Tract Cancer

/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company has completed the rolling submission of a Biologics License...

7 Biotech Stocks to Buy as Sector Rotation Ramps Up

With digital innovation possibly getting overextended, now’s the time to consider biotech stocks for an incoming rotation.

Jazz Pharmaceuticals to Host Virtual Zanidatamab R&D Day on Tuesday, March 19, 2024

/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) will host a virtual R&D Day, Tuesday, March 19, from 8:00 a.m. to 10:00 a.m. ET, focused on...

Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2023 Financial Results and Provides 2024 Financial Guidance

/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the full year and fourth quarter of 2023 and provided guidance...

Jazz Pharmaceuticals Appoints Patrick Kennedy to its Board of Directors

/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the appointment of a new independent director, Patrick Kennedy, to its Board of...

7 Under-the-Radar Biotech Stocks Gearing Up for Liftoff

Although the health innovation space can be a risky environment, undervalued biotech stocks can take some of the edge off.

4 Exhilarating Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip

The Nasdaq Composite is the only major stock index that hasn't put the 2022 bear market in the rearview mirror. For patient investors, it means bargains still abound.

Jazz Pharmaceuticals names Philip Johnson as CFO (NASDAQ:JAZZ)

Jazz Pharmaceuticals announces Philip Johnson as new CFO, effective March 1, 2024.

Jazz Pharmaceuticals Appoints Philip Johnson as Chief Financial Officer

/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz" or the "Company") today announced that Philip Johnson has been appointed Executive Vice...

3 Cannabis Stocks That Could Be Multibaggers in the Making: February Edition

Don’t miss out, as the following cannabis stocks are severely undervalued and are set to increase sales and make huge profits in 2024.

Jazz Pharmaceuticals to Participate in Upcoming March Investor Conferences

/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Company management will participate in the following investor conferences: TD...

Jazz Pharmaceuticals to Report 2023 Full Year and Fourth Quarter Financial Results on February 28, 2024

/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2023 full year and fourth quarter financial results on...

Jazz Pharmaceuticals Larger Than S&P 500 Component Pinnacle West Capital

3 Biotech Stocks to Buy on the Dip: February 2024

Here are three biotech stocks to buy that are trading at prices that may not account for potential breakthrough opportunities

Jazz Pharmaceuticals to buy global rights to KRAS inhibitor program (NASDAQ:JAZZ)

Jazz Pharmaceuticals to acquire Redx's KRAS inhibitor program, expanding its oncology pipeline and aiming to improve treatment options for cancer patients.

Jazz Pharmaceuticals Enters Definitive Agreement with Redx Pharma to Acquire Global Rights to KRAS Inhibitor Program

/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Redx Pharma plc (AIM: REDX) today announced that the companies have signed a definitive agreement...

3 Strong Buy Biotech Stocks to Add to Your February Must-Watch List

These biotech stocks offer investors huge potential in the future. Investors may want to consider these equities to enter the industry.

4 Eye-Catching Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip

The growth-fueled Nasdaq Composite remains nearly 6% below its all-time high, which means amazing deals can still be found.

Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for January 2024

Biotech stocks are warming up in January and look to continue upward in 2024 as the economy improves. Here are three to check out.

2 Incredible Growth Stocks That Are Screaming Buys for 2024

These healthcare businesses are compelling buys for very different reasons.

4 Remarkable Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip

The growth-fueled Nasdaq Composite remains 7% below its all-time high, which means bargains can still be found.

7 Growth Stocks Poised to Thrive in a Post-Fed Pivot World

If the Federal Reserve loosens the monetary spigot, these companies could represent the growth stocks to buy now.

Jazz Pharma PTSD mid-stage trial fails to meet main goal (NASDAQ:JAZZ)

Jazz Pharmaceuticals (JAZZ) on Thursday said a mid-stage trial of JZP150 for the treatment of PTSD failed to meet the main goal of the study. Read more here.

Jazz Pharmaceuticals Provides Update on Phase 2 Trial of Investigational JZP150 in Adult Patients with Post-Traumatic Stress Disorder

/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced top-line results from the Phase 2 trial (NCT05178316) evaluating JZP150, an...

Jazz Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will webcast its corporate presentation at the 42nd Annual J.P. Morgan...